Boehringer Ingelheim and Lilly welcome new recommendation for Jardiance tablets in updated ADA's 2017 Standards

Guidelines include new recommendation to consider the use of Jardiance in people with type 2 diabetes and established cardiovascular disease to reduce the risk of cardiovascular death.

People with diabetes are two to four times more likely to develop cardiovascular disease than people without diabetes. Cardiovascular disease is the leading cause of death associated with diabetes, so it is imperative that adults with type 2 diabetes have treatment options that can help reduce this risk.

"Boehringer Ingelheim and Lilly commend the ADA's commitment to addressing the critical connection between type 2 diabetes and increased cardiovascular risk," said Thomas Seck, vice president, Clinical Development and Medical Affairs, Primary Care, Boehringer Ingelheim Pharmaceuticals. "These important new recommendations recognize the latest scientific evidence and highlight the role of Jardiance for reducing the risk of cardiovascular death in people with type 2 diabetes and established cardiovascular disease and represent an important advance for patient care."

The recommendation is based on breakthrough evidence from the landmark EMPA-REG OUTCOME trial, which investigated the effects of Jardiance compared with placebo when added to standard of care type 2 diabetes and cardiovascular medicines in adults with type 2 diabetes and established cardiovascular disease. On 2 December, the FDA approved a new indication for Jardiance to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.